Journals / Sakarya Tıp Dergisi / 2019 / Cilt: 9 - Sayı: 1

Assessment of the Therapeutic Effects of Zoledronic Acid on Breast Cancer Subtypes

Zoledronik Asidin Meme Kanseri Alt Tiplerinde Terapötik Etkisinin Değerlendirilmesi

Pages
92–102
Publication Date
2019-03-20
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, although ZOL has a potential therapeutic effect on different subtypes of breast cancer, ZOL causes more cytotoxic effects and apoptotic death in triple negative breast cancer (MDA-MB-231) cells than hormone sensitive (MCF-7) cells.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Breast cancer is a heterogeneous type of cancer with many subtypes and is the most common cancer among women.
📊
Key Findings & Data:In the present study, we aimed to investigate the therapeutic effect of a bisphosphonate inhibitor zoledronic acid (ZOL), which is a clinically used in the treatment of cancer types with bone metastases and has been found to exert anti-proliferative and anti-metastatic effects, on two different subtypes of breast cancer [MCF-7 (ER+, PR+, HER2-) and MDA-MB-231 (ER-, PR-, HER2-)] and HUVEC control cells.
💡
Conclusion & Impact:Conclusion: In conclusion, although ZOL has a potential therapeutic effect on different subtypes of breast cancer, ZOL causes more cytotoxic effects and apoptotic death in triple negative breast cancer (MDA-MB-231) cells than hormone sensitive (MCF-7) cells.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Meme kanseri · meme kanseri alt tipleri · zoledronik asit

Abstract

Objective: Breast cancer is a heterogeneous type of cancer with many subtypes and is the most common cancer among women. It is noteworthy that breast cancer subtype-based treatment options have attracted great attention. In the present study, we aimed to investigate the therapeutic effect of a bisphosphonate inhibitor zoledronic acid (ZOL), which is a clinically used in the treatment of cancer types with bone metastases and has been found to exert anti-proliferative and anti-metastatic effects, on two different subtypes of breast cancer [MCF-7 (ER+, PR+, HER2-) and MDA-MB-231 (ER-, PR-, HER2-)] and HUVEC control cells. Materials and Methods: The cytotoxic and apoptotic effect of ZOL (10-100 uM) for 24 and 48 hours was determined by WST-1, Annexin V and cell cycle analysis. In addition, changes in cell morphology and nucleus after treatment with ZOL observed by acridine orange (AO) and DAPI staining, respectively.Results: ZOL caused more anti-proliferative effect and early and late apoptotic death in MDA-MB-231 cells compared with MCF-7 cells (p<0.05). The cell population in G0/G1 phase was significantly increased after treatment with especially 50 and 100 µM ZOL (p <0.05). Additionally, the loss of cell membrane integrity and chromatin condensation were observed in MCF-7 and MDA-MB-231 cells treated with ZOL. However, ZOL had a toxic effect on HUVEC cells at higher concentrations. Conclusion: In conclusion, although ZOL has a potential therapeutic effect on different subtypes of breast cancer, ZOL causes more cytotoxic effects and apoptotic death in triple negative breast cancer (MDA-MB-231) cells than hormone sensitive (MCF-7) cells. However, further studies are needed to determine the molecular mechanisms underlying the therapeutic effect of ZOL depending on subtypes of breast cancer and the optimal schedule and dose of ZOL.

Özet

Amaç: Meme kanseri kadınlarda en sık görülen ve farklı alt tiplere ayrılan heterojen bir kanser türüdür. Bu nedenle, meme kanseri alt tiplerine özgü tedavi yaklaşımları dikkat çekmektedir. Mevcut çalışmada, kemik metastazı görülen kanser tiplerinin tedavisinde klinikte kullanılan ve anti-proliferatif, ve anti-metastatik etkiye sahip olduğu bilinen bir bifosfonat inhibitörü zoledronik asitin (ZOL)’ün, iki farklı meme kanseri alt tipinde [MCF-7 (ER+, PR+, HER2-) ve MDA-MB-231 (ER-, PR-, HER2-)] ve HUVEC kontrol hücrelerinde terapötik etkisinin araştırılması amaçlanmıştır. Gereç ve Yöntem: ZOL’ün (10-100 µM) 24 ve 48 saat boyunca sitotoksik ve apoptotik etkisi WST-1, Annexin V ve hücre siklusu analizleri ile belirlenmiştir. Ayrıca ZOL’ün, hücrelerde ve nukleusda neden olduğu morfolojik değişimler sırasıyla akridin oranj (AO) ve DAPI boyaması ile görüntülenmiştir. Bulgular: ZOL’ün MCF-7 hücrelerine göre, MDA-MB-231 hücrelerinde daha fazla anti-proliferatif etkiye ve erken ve geç apoptotik ölüme neden olduğu analiz edilmiştir (p<0.05). Özellikle 50 ve100 µM ZOL uygulanan hücrelerde G0/G1 fazında hücre miktarının anlamlı bir şekilde arttığı saptanmıştır (p<0.05). Bunun yanı sıra, ZOL uygulanan MCF-7 ve MDA-MB-231 hücrelerinde, hücre membran bütünlüğünde bozulma ve kromatin yoğunlaşması gözlemlenmiştir. Ancak, yüksek konsantrasyonlarda ZOL’ün HUVEC hücrelerinde toksik etkiye neden olduğu belirlenmiştir. Sonuç: Sonuç olarak, ZOL’ün farklı meme kanseri alt tiplerinde potansiyel terapötik etkiye sahip olduğu belirlenmekle birlikte, triple negatif meme kanseri (MDA-MB-231) hücrelerinde, hormon duyarlı (MCF-7) hücrelere göre daha fazla sitotoksik etkiye ve apoptotik ölüme neden olduğu tespit edilmiştir. Ancak, ZOL’ün meme kanseri alt tipine bağlı olarak değişen terapötik etkisine neden olan moleküler mekanizmaların ve ideal uygulama protokolünün belirlenmesine yönelik detaylı çalışmalara ihtiyaç bulunmaktadır.

🔖

Cite This Article

ESKİLER, G. G., ÖZKAN, A. D., BİLİR, C., KALELİ, S. (2019). Assessment of the Therapeutic Effects of Zoledronic Acid on Breast Cancer Subtypes. Sakarya Tıp Dergisi, Cilt: 9 - Sayı: 1, 92–102. https://ajindex.com/articles/261615

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA oncology 2017; 3(4):524-548
  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6):394-424
  3. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 2012; 109:2724–2729
  4. Sonnenblick A, Fumagalli D, Sotiriou C, Piccart M. Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up? Cancer Treat Rev 2014; 40:1089-1095
  5. Sharp A, Harper-wynne C. Treatment of advanced breast cancer (ABC): The expanding landscape of targeted therapies. J cancer Biol Res 2014; 2:1-5
  6. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: How special are they? Mol Oncol 2010; 4:192-208
  7. Eroglu A, Çiçek E. Meme kanserinde moleküler alt tiplere göre cerrahi tedavi yaklaşımları. Yeni Tıp Dergisi 2014; 31(2): 83-87
  8. Eliyatkin N, Yalcin E, Zengel B, Aktaş S, Vardar E. Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. J Breast Heal 2015; 11:59-66
  9. Nguyen DX, Bos PD, Massague J. Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 2009; 9:274-284
  10. Lan YC, Chang CL, Sung MT, Yin PH, Hsu CC, Wang KC, et al. Zoledronic acid-induced cytotoxicity through endoplasmic reticulum stress triggered REDD1-mTOR pathway in breast cancer cells. Anticancer Res 2013; 33(9):3807-3814
  11. Winter MC, Holen I, Coleman RE. Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008; 34:453-475
  12. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013; 126:13-20
  13. Delmas PD. Treatment of postmenopausal osteoporosis. Lancet 2002; 359:2018-2026
  14. Neville-Webbe HL, Coleman RE. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone dise